Ads
related to: anticoagulant drugs- Request a Representative
Request To Be Contacted By A
RIGEL Representative Today
- Treating With TAVALISSE
Learn More from Dr. Craig Kessler
Regarding the Novel Way To Treat
- Patient Cases
Review Patient Cases To See How
TAVALISSE May Work For Your Patient
- Resource Library
Download A Variety Of Clinical
Resources For You & Your Patients
- Explore Efficacy Data
Learn More From Dr. Ralph Boccia
See Trial Program Results
- Dosing Information
Learn How To Dose For Your Patients
Download The Dosing Brochure
- Request a Representative
Search results
Designing reversible anticoagulants
Nature· 6 days agoDiscover the world’s best science and medicine | Nature.com
Common heart problem ‘carries higher stroke and dementia risk than expected’
PA Media: Science via Yahoo News· 21 hours agoAmong these they identified 36,340 AF patients who had no history of stroke, a low perceived risk of...
Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating...
Morningstar· 3 days agoTecarfarin, which recently received Orphan Drug Designation from the FDA for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device ...
If You're Healthy, Daily Fish Oil Supplements Might Come With a Risk
Verywell Health via Yahoo News· 1 day agoThe BMJ Medicine study showed that for participants with heart disease, fish oil supplements were...
Poisons targeting rodents are showing up in other wildlife
New Hampshire Union Leader· 5 days agoLast year, Maria Colby started seeing an alarming increase in the number of owls and hawks coming to...
Key Endoscopy Studies That Could Transform Your Practice
Medscape· 6 days agoDr David Johnson provides insight on 11 studies from this year's Digestive Disease Week, including...
Seaweed - The Next Trendy Superfood?
Mercola· 7 days agoData from the market research firm Mintel said that kelp seaweed could be the next rising superfood. According to a Food Navigator article,2 the firm’s data, which was acquired through their ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Forrest City Times-Herald· 5 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
3D-printed grafts: a breakthrough in combating pos | Newswise
Newswise· 6 days agoA new study presents the development of 3D printed electrospun vascular grafts infused with...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 6 days agoBlueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib) PR Newswire CAMBRIDGE, Mass., May ...